In double-blind cross-over studies in 46 patients with rheumatoid arthritis and in 42 patients with osteoarthrosis of the hip, Orudis-a new non-steroidal antiinflammatory agent-has been shown to be well tolerated and to have comparable therapeutic efficacy with indomethacin when given in equal dosage. Side effects were less severe with Orudis. The results suggest that Orudis will prove valuable in the clinical management of rheumatic diseases.
Introduction
A major problem in the management of inflammatory and degenerative arthritis has been to find an anti-inflammatory analgesic drug which combines potency with safety. Thus the well-established agents in current use, including salicylates, corticosteroids, phenylbutazone, and indomethacin, have ulcerogenic properties as well as other serious toxic or side effects, while the efficacy of other, safer drugs such as ibuprofen has been questioned (Hart, 1972; Owen-Smith and Burry, 1972) . Orudis, 2-(3-benzoylphenyl) propionic acid, is well tolerated by patients and has a very low incidence of side effects and toxic reactions (Cathcart et al., 1972; Gomez, 1972; Mason et al., 1972) ; in particular, overt gastrointestinal bleeding has not been reported. Laboratory studies have shown its potency as an anti-inflammatory agent in animals (Julou et al., 1971) , and recent double-blind cross-over studies against placebo have shown it to have great potency in man (Cathcart et al., 1972; Mason et al., 1972) . The (much worse, worse, unchanged, better, much better) were scored on a five-point scale grading severity of disease from 0 to 4. Duration of morning stiffness (more than 3 hours, 1-3 hours, less than 1 hour, nil) was based on a 0 to 3 scale. At the end of the trial patients were asked to state a preference for the treatment given. Objective assessments were of grip strength (based on the mean of three measurements obtained from each hand with the bag inflated to 30 mm Hg), articular index (Ritchie et al., 1968) , and joint size (Boardman and Hart, 1967) . The number of paracetamol tablets used (rescue-drug count) provided an indication of the relative efficacy of study and reference drugs in suppressing pain.
Study 2.-Subjective assessments were based on answers to agreed questions. Severity of overall pain, night pain, and morning pain, functional grading, global assessment of current clinical state, and comparative global assessment were based on a five-point scale as for study 1, and, similarly, patients were asked to state a preference for one of the two treatments given. Objective assessments were of intermalleolar straddle and intercondylar distance (Owen-Smith and Burry, 1972) , and were recorded as the mean of measurements taken when first pain started and at maximum displacement tolerated by the patient. The rescue-drug count, as with study 1, provided an indirect objective assessment.
In both studies all medicine containers were returned at the end of each treatment period, any remaining capsules and tablets were counted, and the number taken during the trial was calculated.
Side effects were noted at each assessment in response to the questions: Has the treatment upset you in any way during the past two weeks ? If yes, in what way ?
Laboratory investigations undertaken at each assessment were: full blood count, E.S.R. (Westergren), plasma alkaline phosphatase, bilirubin, urea, aspartate transferase, serum hydroxybutyric dehydrogenase, and urine analysis.
Results
Forty-six patients with rheumatoid arthritis completed the trial (Table I) . Of the four patients excluded from the analysis two developed exacerbation of symptoms, one during the Orudis 398 treatment and the other when on indomethacin, and two were withdrawn after administrative errors. Side effects were experienced by 22 patients-in 4 cases only when on Orudis, in 5 only when on indomethacin, and in 12 when on both drugs.
The results are summarized in Tables II and III. Of the patients with osteoarthrosis 42 completed the trial (Table IV) Results from the two trials showed that there was little difference between the two drugs, the only variables-out of 20 investigated-in which differences reached statistically significant proportions were in respect of the number of paracetamol tablets taken for pain relief in the rheumatoid arthritis trial (P <0 05) and the changes in functional dependency in the osteoarthrosis trial (P <0 004). Both these results favoured indomethacin. Significant improvementin functionaldependency was seen only in the group starting treatment with indomethacin, and was absent in the group taking the drugs in the reverse order. Since the two treatment groups were not well matched with regard to functional dependency, in that the group taking indomethacin first contained fewer patients in the more severely incapacitated grades, it seems likely that the result was related to this disparity.
Despite the fact that patients known to be intolerant of indomethacin were excluded from the trial side effects were more frequent with indomethacin and tended to be more severe, particularly with regard to symptoms referable to the central nervous system (Table VII) . In no case, however, were they sufficiently severe to warrant stopping treatment.
Biological Monitoring.-In a number of instances with either drug the serum hydroxybutyric dehydrogenase concentration became increased above the normal range. These changes were not associated with change in bilirubin, alkaline phosphatase, or aspartate transferase concentration, and probably were not significant. Significant changes did not occur elsewhere. Gomez, 1972; Mason et al., 1972) have indicated that in the dosage used in the present study Orudis is well tolerated, causes only occasional and minor side effects, and has statistically significant superiority (P <0-01) in antiinflammatory and analgesic activity when compared with placebo.
Indomethacin is a powerful anti-inflammatory and analgesic drug (Percy et al., 1964; Hart and Boardman, 1965; Thompson and Percy, 1966) , its principal disadvantage being a relatively high incidence of side effects.
The present studies suggest that in equal dosage clinical efficacy of Orudis is comparable with that of indomethacin. The results marginally favour the latter drug but side effects were less severe with the former. Preliminary results from studies with higher dosages of Orudis (Gomez, 1972; Mason et al., 1972) indicate that 150 mg daily is well tolerated. This finding considered together with the above results suggests that Orudis is likely to have an important part to play in the clinical management of rheumatic disease.
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